Clinical Correlates of Cerebrospinal Fluid 14-3-3 Protein in Non-Prion Rapid Progressive Dementia
Journal of Alzheimer's Disease · 2023
DOI: 10.3233/jad-220718 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer's Disease, 2023. Verfasst von Yu Kong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Myoclonus, Creutzfeldt-Jakob Syndrome, Autoimmune Diseases of the Nervous System. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Background
The 14-3-3 protein in cerebrospinal fluid (CSF) is a suitable biomarker for the diagnosis of Creutzfeldt-Jakob disease (CJD). However, it has also been detected in various non-prion-related rapidly progressive dementia (RPD), which affected its diagnostic performance and clinical utilization.
Objective
To investigate the general disease distribution with positive 14-3-3 result and to evaluate the association between CSF 14-3-3 protein and the clinical features in patients with non-prion RPD.
Methods
A total of 150 patients with non-prion RPD were enrolled. The clinical data were collected and CSF 14-3-3 test was performed for all patients. The distribution of various diseases with a positive 14-3-3 result was analyzed and the association of CSF 14-3-3 with clinical features was tested.
Results
The CSF 14-3-3 protein was detected in 23.3% of non-prion RPD patients, and the most frequent diagnoses were autoimmune encephalitis (22.9%) and neurodegenerative disease (22.9%). CSF 14-3-3 protein was more common in older patients (p = 0.028) and those presenting myoclonus (p = 0.008). In subgroup analysis, the positive 14-3-3 test was more common in neurodegenerative disease with a long time from the symptom onset to CSF 14-3-3 test (p = 0.014).
Conclusion
CSF 14-3-3 protein could be detected in a broad spectrum of non-prion RPD. In particular, patients with autoimmune encephalitis and rapidly progressive neurodegenerative diseases and those with myoclonus have a greater likelihood of a positive 14-3-3 result. These results could help clinicians interpret the results of CSF 14-3-3 protein more reasonably.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
- State Key Laboratory of Infectious Disease Prevention and Control, NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Contr…
Zitieren
APA
Kong, Y., Chen, Z., Shi, Q., Zuo, Y., & Zhang, J. (2023). Clinical Correlates of Cerebrospinal Fluid 14-3-3 Protein in Non-Prion Rapid Progressive Dementia. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-220718
Vancouver
Kong Y, Chen Z, Shi Q, Zuo Y, Zhang J. Clinical Correlates of Cerebrospinal Fluid 14-3-3 Protein in Non-Prion Rapid Progressive Dementia. Journal of Alzheimer's Disease. 2023. doi:10.3233/jad-220718
BibTeX
@article{Kong2023,
author = {Kong, Yu and Chen, Zhongyun and Shi, Qi and Zuo, Ya and Zhang, Jing},
title = {Clinical Correlates of Cerebrospinal Fluid 14-3-3 Protein in Non-Prion Rapid Progressive Dementia},
journal = {Journal of Alzheimer's Disease},
year = {2023},
doi = {10.3233/jad-220718}
}
EUVIMED